Essential differences in ligand presentation and T cell epitope recognition among HLA molecules of the HLA‐B44 supertype
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Human leukocyte antigens (HLA) have long been grouped into supertypes to facilitate peptide‐based immunotherapy. Analysis of several hundreds of peptides presented by all nine antigens of the HLA‐B44 supertype (HLA‐B*18, B*37, B*40, B*41, B*44, B*45, B*47, B*49 and B*50) revealed unique peptide motifs for each of them. Taking all supertype members into consideration only 25 out of 670 natural ligands were found on more than one HLA molecule. Further direct comparisons by two mass spectrometric methods – isotope labeling as well as a label‐free approach – consistently demonstrated only minute overlaps of below 3% between the ligandomes of different HLA antigens. In addition, T cell reactions of healthy donors against immunodominant HLA‐B*44 and HLA‐B*40 epitopes from EBV lacked promiscuous T‐cell recognition within the HLA‐B44 supertype. Taken together, these results challenge the common paradigm of broadly presented epitopes within this supertype.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Most members of the B44 supertype share a preference for peptides with Glu (E) at anchor position P2 and polar and hydrophobic residues at the C terminus (Fig. 2J) (54, 56).”
From Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy (2018) · cites this paper as [54]
Citations
Cites
SYFPEITHI: database for MHC ligands and peptide motifs
Rammensee, H. G., Bachmann, J., Emmerich, N. P. N., Bachor, O. A., & Stevanović, S. (1999) · Immunogenetics · doi:10.1007/s002510050595 · Cited by 2,314
Self-citationBarnstable, C. (1978) · Cell · doi:10.1016/0092-8674(78)90296-9 · Cited by 1,916
IMGT/HLA and IMGT/MHC: sequence databases for the study of the major histocompatibility complex
Robinson, J. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg070 · Cited by 810
ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum
Serwold, T., Gonzalez, F., Kim, J., Jacob, R., & Shastri, N. (2002) · Nature · doi:10.1038/nature01074 · Cited by 628
Cao, K., Hollenbach, J., Shi, X., Shi, W., Chopek, M., & Fernández-Viña, M. A. (2001) · Human Immunology · doi:10.1016/s0198-8859(01)00298-1 · Cited by 465
Optimization of the MHC Class I Peptide Cargo Is Dependent on Tapasin
Williams, A. P., Peh, C. A., Purcell, A. W., McCluskey, J., & Elliott, T. (2002) · Immunity · doi:10.1016/s1074-7613(02)00304-7 · Cited by 353
Reits, E., Griekspoor, A., Neijssen, J., Groothuis, T., Jalink, K., van Veelen, P., Janssen, H., Calafat, J., Drijfhout, J. W., & Neefjes, J. (2003) · Immunity · doi:10.1016/s1074-7613(02)00511-3 · Cited by 299
Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs
Sidney, J., Grey, H. M., Kubo, R. T., & Sette, A. (1996) · Immunology Today · doi:10.1016/0167-5699(96)80542-1 · Cited by 260
Macdonald, W. A., Purcell, A. W., Mifsud, N. A., Ely, L. K., Williams, D. S., Chang, L., Gorman, J. J., Clements, C. S., Kjer-Nielsen, L., Koelle, D. M., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030066 · Cited by 204
Integrated functional genomics approach for the design of patient-individual antitumor vaccines.
Weinschenk, T., Gouttefangeas, C., Schirle, M., Obermayr, F., Walter, S., Schoor, O., Kurek, R., Loeser, W., Bichler, K., Wernet, D., et al. (2002) · PubMed · Cited by 203
Self-citationStructural and genetic analyses of HLA class I molecules using monoclonal xenoantibodies
REBAÏ, N., & MALISSEN, B. (1983) · Tissue Antigens · doi:10.1111/j.1399-0039.1983.tb01176.x · Cited by 196
Several HLA alleles share overlapping peptide specificities.
Sidney, J., del Guercio, M. F., Southwood, S., Engelhard, V. H., Appella, E., Rammensee, H. G., Falk, K., Rötzschke, O., Takiguchi, M., Kubo, R. T., et al. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.1.247 · Cited by 194
Self-citationMolecular structure of human histocompatibility antigens: the HLA‐C series
Snary, D., Barnstable, C. J., Bodmer, W. F., & Crumpton, M. J. (1977) · European Journal of Immunology · doi:10.1002/eji.1830070816 · Cited by 181
The peptide-binding motif for the human transporter associated with antigen processing.
van Endert, P. M., Riganelli, D., Greco, G., Fleischhauer, K., Sidney, J., Sette, A., & Bach, J. F. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.6.1883 · Cited by 181
Low HLA-C expression at cell surfaces correlates with increased turnover of heavy chain mRNA.
McCutcheon, J. A., Gumperz, J., Smith, K. D., Lutz, C. T., & Parham, P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.181.6.2085 · Cited by 177
Zernich, D., Purcell, A. W., Macdonald, W. A., Kjer-Nielsen, L., Ely, L. K., Laham, N., Crockford, T., Mifsud, N. A., Bharadwaj, M., Chang, L., et al. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031680 · Cited by 160
Weinzierl, A. O., Lemmel, C., Schoor, O., Müller, M., Krüger, T., Wernet, D., Hennenlotter, J., Stenzl, A., Klingel, K., Rammensee, H.-G., et al. (2007) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m600310-mcp200 · Cited by 130
Self-citationStructural principles that govern the peptide-binding motifs of class I MHC molecules
Zhang, C., Anderson, A., & DeLisi, C. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.1982 · Cited by 127
Identifiying Human MHC Supertypes Using Bioinformatic Methods
Doytchinova, I. A., Guan, P., & Flower, D. R. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.7.4314 · Cited by 126
Toward a Definition of Self: Proteomic Evaluation of the Class I Peptide Repertoire
Hickman, H. D., Luis, A. D., Buchli, R., Few, S. R., Sathiamurthy, M., VanGundy, R. S., Giberson, C. F., & Hildebrand, W. H. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.5.2944 · Cited by 110
Differential quantitative analysis of MHC ligands by mass spectrometry using stable isotope labeling
Lemmel, C., Weik, S., Eberle, U., Dengjel, J., Kratt, T., Becker, H. D., Rammensee, H., & Stevanović, S. (2004) · Nature Biotechnology · doi:10.1038/nbt947 · Cited by 95
Self-citationKrüger, T., Schoor, O., Lemmel, C., Kraemer, B. F., Reichle, C., Dengjel, J., Weinschenk, T., Müller, M., Hennenlotter, J., Stenzl, A., et al. (2004) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-004-0650-5 · Cited by 75
Self-citationWeinzierl, A. O., Maurer, D., Altenberend, F., Schneiderhan‐Marra, N., Klingel, K., Schoor, O., Wernet, D., Joos, T. O., Rammensee, H., & Stevanović, S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2540 · Cited by 51
Self-citationBurrows, S. R., Elkington, R., Miles, J. J., Green, K. J., Walker, S., Haryana, S. M., Moss, D. J., Dunckley, H., Burrows, J. M., & Khanna, R. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.3.1407 · Cited by 50
Davenport, M. P., Smith, K. J., Barouch, D. H., Reid, S. W., Bodnar, W. M., Willis, A. C., Hunt, D. F., & Hill, A. V. S. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.2.367 · Cited by 50
Simultaneous Prediction of Binding Capacity for Multiple Molecules of the HLA B44 Supertype
Sidney, J., Southwood, S., Pasquetto, V., & Sette, A. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.11.5964 · Cited by 49
Bihl, F. K., Loggi, E., Chisholm, J. V., Hewitt, H. S., Henry, L. M., Linde, C., Suscovich, T. J., Wong, J. T., Frahm, N., Andreone, P., et al. (2005) · Journal of Translational Medicine · doi:10.1186/1479-5876-3-20 · Cited by 39
Schipper, R. F., van Els, C. A. C. M., D'Amaro, J., & Oudshoorn, M. (1996) · Human Immunology · doi:10.1016/s0198-8859(96)00138-3 · Cited by 32
Takedatsu, H., Shichijo, S., Katagiri, K., Sawamizu, H., Sata, M., & Itoh, K. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0797-3 · Cited by 31
Amino acid 95 causes strong alteration of peptide position PΩ in HLA-B*41 variants
Bade‐Doeding, C., DeLuca, D. S., Seltsam, A. W., Blasczyk, R., & Eiz‐Vesper, B. (2007) · Immunogenetics · doi:10.1007/s00251-007-0197-7 · Cited by 25
Thorpe, C. J., & Travers, P. (1994) · Immunogenetics · doi:10.1007/bf00189977 · Cited by 16
Cited by
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
Chowell, D., Morris, L. G. T., Grigg, C. M., Weber, J. K., Samstein, R. M., Makarov, V., Kuo, F., Kendall, S. M., Requena, D., Riaz, N., et al. (2018) · Science · doi:10.1126/science.aao4572 · Cited by 1,142
MHC Class II epitope predictive algorithms
Nielsen, M., Lund, O., Buus, S., & Lundegaard, C. (2010) · Immunology · doi:10.1111/j.1365-2567.2010.03268.x · Cited by 236
Chu, Y., Zhang, Y., Wang, Q., Zhang, L., Wang, X., Wang, Y., Salahub, D. R., Xu, Q., Wang, J., Jiang, X., et al. (2022) · Nature Machine Intelligence · doi:10.1038/s42256-022-00459-7 · Cited by 187
Major histocompatibility complex class I binding predictions as a tool in epitope discovery
Lundegaard, C., Lund, O., Buus, S., & Nielsen, M. (2010) · Immunology · doi:10.1111/j.1365-2567.2010.03300.x · Cited by 140
Metadata
- Authors
- Hillen, N., Mester, G., Lemmel, C., Weinzierl, A. O., Müller, M., Wernet, D., Hennenlotter, J., Stenzl, A., Rammensee, H., & Stevanović, S.
- Affiliations
- University of Tübingen (DE)
- Corresponding author
- Stevanović, Stefan
- Venue
- European Journal of Immunology
- Publisher
- Wiley
- Published
- 2008-11
- Volume
- 38
- Issue
- 11
- Pages
- 2993-3003
- ISSN
- 0014-2980 (ISSN-L)
- 1521-4141
- OpenAlex
- W2064890497
- Cited by
- 43
- References
- 31
- Citations by year
- 2025: 1 · 2024: 1 · 2022: 2 · 2020: 2 · 2019: 2 · 2017: 4 · 2016: 2 · 2015: 6 · 2014: 4 · 2013: 3 · 2012: 2
- FWCI
- 1.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- HLA-B44, HLA-B40, T cell epitope recognition, immunodominant epitopes, HLA supertypes, isotopic labeling, label-free mass spectrometry
- MeSH terms
- Humans, Ligands, HLA-B Antigens, Antigen Presentation, CD8-Positive T-Lymphocytes, Epitopes, T-Lymphocyte, Amino Acid Motifs, Cell Line, Tumor, HLA-B44 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.